<!DOCTYPE html>
<html lang="en"><head>
<script src="hipofiz-hastaliklari_files/libs/clipboard/clipboard.min.js"></script>
<script src="hipofiz-hastaliklari_files/libs/quarto-html/tabby.min.js"></script>
<script src="hipofiz-hastaliklari_files/libs/quarto-html/popper.min.js"></script>
<script src="hipofiz-hastaliklari_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="hipofiz-hastaliklari_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="hipofiz-hastaliklari_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="hipofiz-hastaliklari_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="hipofiz-hastaliklari_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.296">

  <meta name="author" content="Serdar Balcı">
  <title>Hipofiz Hastalıkları</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="hipofiz-hastaliklari_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="hipofiz-hastaliklari_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="hipofiz-hastaliklari_files/libs/revealjs/dist/theme/quarto.css" id="theme">
  <link href="hipofiz-hastaliklari_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="hipofiz-hastaliklari_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="hipofiz-hastaliklari_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="hipofiz-hastaliklari_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Hipofiz Hastalıkları</h1>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Serdar Balcı 
</div>
</div>
</div>

</section>
<section id="davutun-golyatı-öldürmesi-i.samuel" class="slide level2">
<h2>Davut’un Golyat’ı Öldürmesi (I.Samuel)</h2>
<p><strong>1.Sa.17: 4 Filist ordugahından Gatlı Golyat adında usta bir dövüşçüortaya çıktı. </strong> <strong>Boyu </strong> <strong>altı arşın bir karıştı*fe*.D Not 17:4 “Altı arşın bir karış”: </strong> <strong>Yaklaşık 2.9 m</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 5 Başına tunç* miğfer takmış, pullu bir zırh kuşanmıştı. </strong> <strong>Tunç zırhın ağırlığı</strong> __ beş bin şekeldi*ff*.D Not 17:5 “Beş bin şekel”: __ <strong>Yaklaşık 57.5 kg</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 6 Baldırları zırhlarla korunmuştu. Omuzları arasında tunç bir pala asılıydı.</strong></p>
<p><strong>1.Sa.17: 7 Mızrağının sapı dokumacı tezgahının sırığı gibiydi. </strong> <strong>Mızrağındemir başının ağırlığı</strong> __ altı yüz şekeldi*fg*. Golyat’ın önüsıra kalkanını taşıyan bir adam yürüyordu.D Not 17:7 “Altı yüz şekel”: __ <strong>Yaklaşık 6.9 kg</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 8 Golyat durup İsrail ordusuna, “Neden savaş düzeni aldınız?” diye haykırdı, “Ben Filistli’yim, sizse Saul’un kölelerisiniz. Aranızdan karşıma çıkacak birini seçin.</strong></p>
<p><strong>1.Sa.17: 38 Sonra kendi giysilerini Davut’a verdi; başına tunç miğfer taktı, ona bir zırh giydirdi.</strong></p>
<p><strong>1.Sa.17: 39 Davut giysilerinin üzerine kılıcını kuşanıp yürümeye çalıştı. Çünkü bu giysilere alışık değildi. Saul’a, “Bunlarla yürüyemiyorum” dedi, “Çünkü alışık değilim.” Sonra giysileri üzerinden çıkardı.</strong></p>
<p><strong>1.Sa.17: 40 Değneğini alıp dereden beş çakıl taşı seçti. Bunları çoban dağarcığının cebine koyduktan sonra </strong> <strong>sapanını alıp Filistli Golyat’a doğru ilerledi</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 48 Golyat saldırmak amacıyla Davut’a doğru ilerledi. Davut daonunla dövüşmek üzere hemen Filist cephesine doğru koştu.</strong></p>
<p><strong>1.Sa.17: 49 </strong> <strong>Elini dağarcığına sokup bir taş çıkardı, sapanla fırlattı.Taş Filistli’nin alnına çarpıp saplandı. Filistli yüzükoyun yere düştü.</strong></p>
<p><strong>1.Sa.17: 50 Böylece Davut Filistli Golyat’ı sapan ve taşla yendi.Elinde kılıç olmaksızın onu yere serdi.</strong></p>
<p><strong>1.Sa.17: 51 Sonra koşup üzerine çıktı. Golyat’ın kılıcını tutupkınından çektiği gibi onu öldürdü ve başını kesti.Kahraman Golyat’ın öldüğünü gören Filistliler kaçtılar.</strong></p>
<p><strong>Pierre Puget ‘David, vainqueur de Goliath’ </strong></p>
<p><em>A History of Acromegaly </em> <strong>Pituitary 1999;2:7–28</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B10.jpg" class="quarto-discovered-preview-image"></p>
<p><strong>Undoubtedly Goliath’s great size was due to </strong> <strong>acromegaly </strong> <strong>secondary to a pituitary macroadenoma. This pituitary adenoma was apparently large enough to induce </strong> <strong>visual field deficits</strong> __ by its pressure on the optic chiasm, which made Goliath __ <strong>unable to follow the young David </strong> <strong>as he circled him. The </strong> <strong>stone entered Goliath’s cranial vault </strong> <strong>through a </strong> <strong>markedly thinned frontal bone</strong> <strong>, which resulted from enlargement of the frontal paranasal sinus, a frequent feature of acromegaly. The stone lodged in Goliath’s enlarged pituitary and caused a </strong> <strong>pituitary hemorrhage</strong> <strong>, resulting in </strong> <strong>transtentorial herniation and death</strong> <strong>.</strong></p>
<p><strong>Radiology. 1990 Jul;176(1):288. </strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B11.jpg"></p>
</section>
<section id="hipofiz-pitüiter-hastalıkları" class="slide level2">
<h2>Hipofiz (Pitüiter) Hastalıkları</h2>
</section>
<section id="dr.-serdar-balci" class="slide level2">
<h2>Dr.&nbsp;Serdar BALCI</h2>
</section>
<section id="hipofiz-pitüiter-bezi" class="slide level2">
<h2>Hipofiz (Pitüiter) bezi</h2>
<ul>
<li><strong>Küçük, fasulye şeklinde</strong></li>
<li><strong>Sella turcica içinde beyin tabanında yer alır</strong></li>
<li><strong>Hipotalamus ile ilişkili</strong>
<ul>
<li><strong>Sap (stalk), aksonlar</strong></li>
<li><strong>Venöz pleksus</strong></li>
</ul></li>
<li><strong>Anterior lob (Adenohipofiz)</strong></li>
<li><strong>Posterior lob (Nörohipofiz)</strong></li>
</ul>
</section>
<section id="adenohipofiz" class="slide level2">
<h2>Adenohipofiz</h2>
<ul>
<li><strong>Epitelyal hücreler</strong></li>
<li><strong>Embriyolojik olarak oral kaviteden gelişir</strong></li>
<li><strong>Normal histoloji:</strong>
<ul>
<li><strong>Sitoplazmalarının rengine göre</strong></li>
<li><strong>Bazofilik, eozinofilik, kromofobik hücrelerden oluşur</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B12.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B13.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B14.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B15.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B16.jpg"></p>
</section>
<section id="hipofiz-hastalıkları" class="slide level2">
<h2>Hipofiz hastalıkları</h2>
<ul>
<li><strong>Hiperpitüitarizm</strong>
<ul>
<li><strong>Trofik hormonların fazla sekresyonu</strong></li>
<li><strong>Anterior bölgede hipofiz adenomu</strong></li>
</ul></li>
<li><strong>Hipopitüitarizm</strong>
<ul>
<li><p><strong>Trofik hormonların yokluğu</strong></p></li>
<li><p><strong>İskemik hasar, cerrahi, radyasyon, diğer inflamatuar reaksiyonlar</strong></p></li>
<li><p><strong>Nonfonksiyone pitüter adenomlar normal yapıları yıkar</strong></p></li>
<li><p><strong>Lokal kitle etkisi</strong></p></li>
<li><p><strong>Sella genişlemesi, kemik erezyonu, sella diafragmasının hasarı</strong></p></li>
<li><p><strong>Optik kiazmadaki çaprazlayan liflere bası</strong></p>
<ul>
<li><strong>lateral (temporal) görme defektleri, bitemporal hemianopsia</strong></li>
</ul></li>
<li><p><strong>İntrakraniyel basınç artışı</strong></p>
<ul>
<li><strong>Başağrısı, bulantı, kusma</strong></li>
</ul></li>
<li><p><strong>Beyin tabanına uzanım</strong></p>
<ul>
<li><strong>İnvaziv hipofiz adenomu</strong></li>
<li><strong>Nöbet veya obstrüktif tip hidrosefalus</strong></li>
<li><strong>Kraniyel sinir felci</strong></li>
</ul></li>
<li><p><strong>Adenom içine akut kanama</strong></p>
<ul>
<li><strong>Lezyonun hızlı genişlemesi</strong></li>
<li><strong>Pitüiter apopleksi</strong></li>
<li><strong>Hızlı ölümcül</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="hiperpitüitarizm" class="slide level2">
<h2>Hiperpitüitarizm</h2>
<ul>
<li><strong>En sık neden anterior lob kaynaklı adenom</strong></li>
<li><strong>Daha az sıklıkla</strong>
<ul>
<li><strong>Hiperplazi</strong></li>
<li><strong>Anterior hipofiz karsinomları</strong></li>
<li><strong>Ekstrapitüiter tümörlerden hormon sekresyonu</strong></li>
<li><strong>Hipotalamik hastalıklar</strong></li>
</ul></li>
</ul>
</section>
<section id="pitüiter-adenom-patogenezi" class="slide level2">
<h2>Pitüiter adenom patogenezi</h2>
<ul>
<li><strong>Guanine nucleotide–binding protein (G protein) mutasyonları</strong></li>
<li><strong>Sinyal iletiminde kritik rolü var</strong>
<ul>
<li><strong>Yüzey reseptörlerden (growth hormone–releasing hormone receptor) intraselüler efektörlere (adenyl cyclase)</strong>
<ul>
<li><strong>Sekonde mesajcılar (cAMP).</strong></li>
</ul></li>
<li><strong>GNAS1 geni ile kodalnır</strong></li>
</ul></li>
<li><strong>GNAS1 mutasyonu</strong>
<ul>
<li><strong>Somatotrop hücre adenomlarının %40</strong></li>
<li><strong>Kortikotrop hücre adenomlarının küçük bir kısmı</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B17.png" class="r-stretch"></section>
<section id="hipofiz-adenomu-patogenezi" class="slide level2">
<h2>Hipofiz adenomu patogenezi</h2>
<ul>
<li><strong>Ailesel hipofiz adenomları</strong>
<ul>
<li><strong>MEN1, CDKN1B, PRKAR1A, and AIP</strong></li>
<li><strong>MEN1 geninde germline inaktivasyon mutasyonları</strong>
<ul>
<li><strong>multiple endocrine neoplasia syndrome type 1 (MEN-1)</strong></li>
</ul></li>
<li><strong>CDKN1B gene</strong>
<ul>
<li><strong>Hücre siklusunda düzenleyici p27 or KIP1</strong></li>
</ul></li>
<li><strong>CDKN1B germline mutasyonlar</strong>
<ul>
<li><strong>“MEN-1 benzeri” sendrom</strong></li>
</ul></li>
<li><strong>Aryl hydrocarbon receptor–interacting protein (AIP)</strong>
<ul>
<li><strong>Hipofiz adenom yatkınlık geni</strong></li>
<li><strong>&lt;35 yaş, GH adenomu</strong></li>
</ul></li>
</ul></li>
<li><strong>TP53 mutasyonları</strong>
<ul>
<li><strong>Agresif davranış, invazyon ve rekürrensle ilişkili</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B18.png"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B19.png"></p>
<p><strong>Makroadenom&gt;1 cm</strong></p>
<p><strong>Mikroadenom&lt;1 cm</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B110.png"></p>
<p><strong>İyi sınırlı, yumuşak kıvamlı lezyon</strong></p>
<p><strong>Küçük tümörler, sella turcica sınırlı</strong></p>
<p><strong>İri tümörle optik kiazma ve komşu yapılara baskı uygular</strong></p>
<p><strong>Sella turcia ve clinoid proses erezyonu</strong></p>
<p><strong>Kavernöz ve sifenoid sinüslere uzanım</strong></p>
<p><strong>%30 olguda kapsülsüz, kemik, dura ve nadiren beyin invazyonu</strong></p>
<p><strong>Kanama ve nekroz büyük iri adenomlarda sık</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B111.png"></p>
<p><strong>Masif, nonfonksiyone adenom, sella turcicayı aşıp beyne bası uygulamış</strong></p>
<p><strong>Nonfonksiyone adenomlar tanı anında fonksiyone adenomlara kıyasla daha iri olurlar</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B112.png"></p>
<p><strong>Uniform poligonal hücreler, tabaka, kord veya papiller görünümde</strong></p>
<p><strong>Destekleyici konnektif doku ya da retikülin çok az</strong></p>
<p><strong>Yumuşak, jelatinöz kıvam</strong></p>
<p><strong>Nükleuslar uniform ya da pleomorfik</strong></p>
<p><strong>Mitotik aktivite genelde çok nadir</strong></p>
<p><strong>Sitoplazma asidofilik, bazofilik ya da kromofobik olabilir, ancak tümör boyunca homojendir</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>anterior hipofiz parankimi</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B113.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B114.png"></p>
<p><strong>Hücresel monomorfizm ve retikülin ağının olmamamsı ile hipofiz adenomu çevre nonneoplastik adenohipofiz dokusundan ayrılabilir</strong></p>
</section>
<section id="hipofiz-adenomu" class="slide level2">
<h2>Hipofiz adenomu</h2>
<ul>
<li><strong>Histolojik inceleme ile fonksiyonel durum güvenle tahmin edilemeyebilir</strong></li>
<li><strong>TP53 mutasyonu gösteren adenomlar</strong>
<ul>
<li><strong>Belirgin mitotik aktivite</strong></li>
<li><strong>Yüksek proliferasyon hızı</strong></li>
<li><strong>“Atipik adenom” diye adlandırılırlar</strong></li>
<li><strong>Agresif davranış potansiyeli var</strong></li>
</ul></li>
<li><strong>Genelde tek hücre tipinden oluşur ve tek tip hormon üretirler</strong></li>
<li><strong>Bazı adenomlar iki farklı hormon sekrete edebilir</strong>
<ul>
<li><strong>GH ve PRL en sık kombinasyon</strong></li>
<li><strong>Nadiren plurihormonal</strong></li>
</ul></li>
<li><strong>Fonksiyonel</strong>
<ul>
<li><strong>Hormon fazlalaığı ve klinik bulguları</strong></li>
</ul></li>
<li><strong>Nonfonksiyone adenomlar</strong>
<ul>
<li><strong>Kitle etkisi, hipopitüitarizm</strong></li>
<li><strong>Hormon ekspresyonu sadece dokuda, immünohistokimya ile gösterilebilir, klinik bulgu yoktur</strong></li>
</ul></li>
<li><strong>Gerçek “hormon negatif”</strong>
<ul>
<li><strong>İmmünohistokimyasal olarak ya da ultrastrüktüler olarak hormon üretimi yok</strong></li>
</ul></li>
<li><strong>Nonfonksiyone ve hormon negatif adenomlar</strong>
<ul>
<li><strong>Geç klinik bulgu verirler</strong></li>
<li><strong>Makroadenom</strong></li>
<li><strong>Hipopitüitarizm</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B115.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="prolaktinom" class="slide level2">
<h2>Prolaktinom</h2>
<p><strong>En sık hiperfonksiyon gösteren adenom</strong></p>
<p><strong>Küçük mikroadenom, büyük kitle etkisi yapabilen adenomlara kadar değişken büyüklük</strong></p>
<p><strong>PRL immünohistokimyasal olarak gösterilebilir</strong></p>
</section>
<section id="hiperprolaktinemi" class="slide level2">
<h2>Hiperprolaktinemi</h2>
<ul>
<li><strong>Amenore, Galaktore, libido kaybı, infertilite</strong></li>
<li><strong>Doğurganlık çağındaki kadınlarda erken dönemde tespit edilir</strong></li>
<li><strong>Erkeklerde ve ileri yaş kadınlarda daha az klinik bulgu</strong>
<ul>
<li><strong>Adenom büyüklüğü tanı sırasında daha büyük</strong></li>
</ul></li>
<li><strong>PRL-adenomu dışı nedenler:</strong>
<ul>
<li><strong>Gebelik</strong></li>
<li><strong>Yüksek doz östrojen tedavisi</strong></li>
<li><strong>Böbrek yetmezliği</strong></li>
<li><strong>Hipotiroidi</strong></li>
<li><strong>Hipotalamik lezyonlar</strong></li>
<li><strong>Dopamin inhibitörleri (reserpine)</strong></li>
<li><strong>Sap (stalk) etkisi</strong>
<ul>
<li><strong>Hipotalamusun inhibitör etkisini kaldıracak kitle etkisi</strong></li>
<li><strong>Serum PRL düzeyindeki hafif yükselmeler (&lt;200 µg/L) PRL dışı başka hipofiz adenomlarında da olabilir</strong></li>
</ul></li>
</ul></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B116.png" class="r-stretch"><p><strong>Robbins and Cotran Pathologic Basis of Disease</strong></p>
</section>
<section id="somatotrop-büyüme-hormonu-growth-hormone-adenomları" class="slide level2">
<h2>Somatotrop (büyüme hormonu / growth hormone) adenomları</h2>
<ul>
<li><strong>En sık ikinci fonksiyonel adenom</strong>
<ul>
<li><strong>GH adenomu</strong></li>
<li><strong>Mikst GH+PRL adenomu</strong></li>
</ul></li>
<li><strong>Klinik bulgular hafif olabilir</strong></li>
<li><strong>Klinik bulgu verdiğinde oldukça büyük olabilir</strong></li>
<li><strong>GH immünohistokimya ile gösterilebilir</strong>
<ul>
<li><strong>Az miktarda PRL ekspresyonu da eşlik edebilir</strong></li>
</ul></li>
<li><strong>Sürekli GH sekresyonu</strong>
<ul>
<li><strong>Hepatositlerden insulin-like growth factor I (somatomedin C) salgılanması</strong>
<ul>
<li><strong>Klinik bulgulara neden olur</strong></li>
</ul></li>
</ul></li>
<li><strong>Epifiz hattı kapanmadan, prepüberte</strong>
<ul>
<li><strong>Gigantizm (Devlik)</strong>
<ul>
<li><strong>Vücut boyutlarında jeneralize artış</strong></li>
<li><strong>Kol ve bacaklarda uygunsuz boy</strong></li>
</ul></li>
</ul></li>
<li><strong>Epifiz hattı kapandıktan sonra</strong>
<ul>
<li><strong>Akromegali</strong>
<ul>
<li><strong>Yumuşak doku, deri, organlar ve el, ayak, yüz kemiklerinde büyüme</strong></li>
<li><strong>Prognatizm</strong>
<ul>
<li><strong>Çenede irileşme ve öne çıkma</strong></li>
<li><strong>Yüzün alt tarfında genişleme ve dişlerde ayrılma</strong></li>
</ul></li>
<li><strong>El ve ayaklarda genişleme</strong></li>
<li><strong>Iri, sosis gibi parmaklar</strong></li>
</ul></li>
</ul></li>
<li><strong>Growth hormone fazlalığı</strong>
<ul>
<li><strong>Anormal glukoz toleransı</strong></li>
<li><strong>diabetes mellitus</strong></li>
<li><strong>Jeneralize kas güçsüzlüğü</strong></li>
<li><strong>Hipertansiyon</strong></li>
<li><strong>Artrit</strong></li>
<li><strong>Osteoporoz</strong></li>
<li><strong>Konjestif Kalp Yetmezliği</strong></li>
</ul></li>
</ul>
</section>
<section id="kortikotrop-acth-üreten-adenomlar" class="slide level2">
<h2>Kortikotrop (ACTH üreten) adenomlar</h2>
<ul>
<li><p><strong>Çoğu tanı anında küçük, mikroadenom</strong></p></li>
<li><p><strong>PAS pozitif</strong></p>
<ul>
<li><strong>Glikolize ACTH birikimi nedeniyle</strong></li>
</ul></li>
<li><p><strong>Immünohistokimya ile ACTH ekspresyonu</strong></p></li>
<li><p><strong>Elektron mikroskobu ile, membrana bağlı elektron yoğun granüller (300nm çap)</strong></p></li>
<li><p><strong>Klinik olarak sessiz</strong></p></li>
<li><p><strong>Hiperkortizolizm</strong></p>
<ul>
<li><strong>Cushing sendromu</strong></li>
<li><strong>ACTH’ın adrenal korteks üzerindeki uyarıcı etkileri</strong></li>
</ul></li>
<li><p><strong>Cushing hastalığı</strong></p>
<ul>
<li><strong>Eğer artmış ACTH hipofiz kaynaklı ise</strong></li>
</ul></li>
<li><p><strong>Nelson sendromu</strong></p>
<ul>
<li><strong>Cushing sendromu tedavisi için cerrahi olarak adrenallerin alınması sonrası gelişen iri, klinik agresif kortikotrop adenomu</strong></li>
<li><strong>Adrenaller alındığında → daha önce var olan mikroadenom üzerindeki geri bildirim kalkar</strong></li>
<li><strong>Kitle etkisi</strong></li>
</ul></li>
</ul>
</section>
<section id="gonadotrop-fsh-ya-da-lh-adenomları" class="slide level2">
<h2>Gonadotrop (FSH ya da LH) adenomları</h2>
<p><strong>Tespiti zor</strong></p>
<p><strong>Hormonları düzensiz ve az salgılar</strong></p>
<p><strong>Hormonlar klinik sendroma yol açmazlar</strong></p>
<p><strong>Kitle etkisi</strong></p>
<p><strong>İmmünohistokimyasal oalrak ortak gonadotropin α-subunit, spesifik β-FSH ve β-LH subunits</strong></p>
<p><strong>FSH genelde daha baskın</strong></p>
</section>
<section id="tirotrop-tsh-adenomları" class="slide level2">
<h2>Tirotrop (TSH) adenomları</h2>
<p><strong>Hipofiz adenomlarının %1’i</strong></p>
<p><strong>Hipertiroidizm</strong></p>
</section>
<section id="nonfonksiyone-adenomlar" class="slide level2">
<h2>Nonfonksiyone adenomlar</h2>
<ul>
<li><strong>Hipofiz adenomlarının %25’i</strong></li>
<li><strong>Kitle etkisi</strong></li>
<li><strong>Hipopitüitarizm</strong></li>
<li><strong>Klinik sakin fonksiyone adenomlar</strong>
<ul>
<li><strong>Sessiz gonadotrop adenomu</strong></li>
</ul></li>
<li><strong>Gerçek hormon negatif (null cell) adenom</strong></li>
</ul>
</section>
<section id="hipofiz-karsinomları" class="slide level2">
<h2>Hipofiz karsinomları</h2>
<p><strong>Çok nadir</strong></p>
<p><strong>Lokal invazyon</strong></p>
<p><strong>Uzak metastaz</strong></p>
</section>
<section id="hipopitüitarizm" class="slide level2">
<h2>Hipopitüitarizm</h2>
<p><strong>Anterior lob parankiminin %75’inden fazlasında kayıp</strong></p>
<p><strong>Konjenital (çok nadir)</strong></p>
<p><strong>Nonfonksiyone hipofiz adenomu</strong></p>
<ul>
<li><p><strong>Anterior hipofizde iskemik nekroz</strong></p>
<ul>
<li><strong>Sheehan sendromu</strong>
<ul>
<li><strong>Doğum sonrası nekroz</strong></li>
<li><strong>Gebelik sırasında bezde fizyolojik genişleme</strong></li>
<li><strong>Bu genişlemeye venöz portal sistem eşlik etmez</strong></li>
<li><strong>Ani kan kaybı ve hipotansiyon iskemiye neden olur</strong></li>
<li><strong>Nörohipofiz etkilenmez, beslenmesi arteryal</strong></li>
</ul></li>
<li><strong>Dissemine intravasküler koagülasyon</strong></li>
<li><strong>Orak hücreli anemi</strong></li>
<li><strong>Artmış intrakraniyel basınç</strong></li>
<li><strong>Travma</strong></li>
<li><strong>Şok</strong></li>
</ul></li>
<li><p><strong>Rezidü bez büzüşmüş ve skar</strong></p></li>
<li><p><strong>Cerrahi ,radyasyon</strong></p></li>
<li><p><strong>İnflamasyon</strong></p>
<ul>
<li><strong>Sarkoidoz, tüberküloz</strong></li>
</ul></li>
<li><p><strong>Travma</strong></p></li>
<li><p><strong>Metastaz</strong></p></li>
</ul>
</section>
<section id="clinical-manifestations-of-anterior-pituitary-hypofunction" class="slide level2">
<h2>Clinical manifestations of anterior pituitary hypofunction</h2>
<ul>
<li><strong>Depend on the specific hormones that are lacking</strong></li>
<li><strong>Growth hormone deficiency</strong>
<ul>
<li><strong>Growth failure (pituitary dwarfism)</strong></li>
</ul></li>
<li><strong>Gonadotropin or gonadotropin-releasing hormone (GnRH) deficiency</strong>
<ul>
<li><strong>amenorrhea and infertility in women</strong></li>
<li><strong>decreased libido, impotence, and loss of pubic and axillary hair in men</strong></li>
</ul></li>
<li><strong>TSH</strong>
<ul>
<li><strong>hypothyroidism</strong></li>
</ul></li>
<li><strong>ACTH</strong>
<ul>
<li><strong>hypoadrenalism</strong></li>
</ul></li>
<li><strong>Prolactin deficiency</strong>
<ul>
<li><strong>failure of postpartum lactation</strong></li>
</ul></li>
<li><strong>Loss of stimulatory effects of MSH on melanocytes</strong>
<ul>
<li><strong>Pallor</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B117.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B118.jpg"></p>
</section>
<section id="posterior-hipofiz-sendromlari" class="slide level2">
<h2>POSTERIOR HIPOFIZ SENDROMLARI</h2>
</section>
<section id="posterior-pituitary-syndromes" class="slide level2">
<h2>Posterior Pituitary Syndromes</h2>
<ul>
<li><strong>Neurohypophysis</strong>
<ul>
<li><strong>composed of modified glial cells (termed pituicytes )</strong></li>
<li><strong>Axonal processes extending from nerve cell bodies in the supraoptic and paraventricular nuclei of the hypothalamus</strong></li>
</ul></li>
<li><strong>Hypothalamic neurons produce two peptides</strong>
<ul>
<li><strong>antidiuretic hormone (ADH) and oxytocin</strong></li>
<li><strong>They are stored in axon terminals in the neurohypophysis</strong></li>
<li><strong>Released into the circulation in response to stimuli</strong></li>
</ul></li>
<li><strong>Oxytocin</strong>
<ul>
<li><strong>stimulates the contraction of smooth muscle in the pregnant uterus</strong></li>
<li><strong>muscle surrounding the lactiferous ducts of the mammary glands</strong></li>
<li><strong>Impairment of oxytocin synthesis and release has not been associated with significant clinical abnormalities</strong></li>
</ul></li>
<li><strong>ADH</strong>
<ul>
<li><strong>diabetes insipidus</strong></li>
<li><strong>secretion of inappropriately high levels of ADH</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B119.jpg" class="r-stretch"></section>
<section id="antidiüretik-hormon" class="slide level2">
<h2>Antidiüretik hormon</h2>
<ul>
<li><strong>Supraoptik nükleus kaynaklı nanopeptid</strong></li>
<li><strong>ADH sekresyon nedenleri</strong>
<ul>
<li><strong>Artmış plazma onkositik basıncı, sol atrial dilatasyonu, egzersiz, duygusal stres</strong></li>
<li><strong>Böbrek toplayıcı duktuslarından su emilimi</strong></li>
</ul></li>
<li><strong>ADH eksikliği diabetes insipidus</strong>
<ul>
<li><p><strong>Poliüri</strong></p></li>
<li><p><strong>Böbrek idrardan suyu yeterli miktarda ememez</strong></p></li>
<li><p><strong>Uygunsuz ADH sekresyonu (SIADH)</strong></p>
<ul>
<li><strong>Fazla su emilimi</strong></li>
<li><strong>Hiponatremi, serebral ödem, nörolojik disfonksiyon</strong></li>
</ul></li>
<li><p><strong>ADH fazlalığı nedenleri:</strong></p>
<ul>
<li><strong>Paraneoplastik</strong>
<ul>
<li><strong>Küçük hücreli akciğer kanseri</strong></li>
</ul></li>
<li><strong>Nonneoplastik akciğer hastalıkları</strong></li>
<li><strong>Hipotalamus veya hipofize lokal hasar</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="hipotalamik-suprasellar-tümörler" class="slide level2">
<h2>HIPOTALAMIK SUPRASELLAR TÜMÖRLER</h2>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B120.png" class="r-stretch"><p><strong>Kraniyofarenjiom</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="kraniyofarenjiom" class="slide level2">
<h2>Kraniyofarenjiom</h2>
<ul>
<li><p><strong>Rathke kesesi artıkları</strong></p></li>
<li><p><strong>İntrakraniyel tümörlerin %1-5</strong></p></li>
<li><p><strong>Çoğu suprasellar, intrasellar uzanım olabilir</strong></p></li>
<li><p><strong>Bimodal yaş dağılımı</strong></p>
<ul>
<li><strong>5-15 yaş</strong></li>
<li><strong>&gt;65 yaş</strong></li>
</ul></li>
<li><p><strong>WNT yolağı, β-catenin mutasyonları</strong></p></li>
<li><p><strong>Ortalama çap 3-4  cm</strong></p></li>
<li><p><strong>Sistik ve bazen multiloküle</strong></p></li>
<li><p><strong>Adamantinomatöz Kraniyofarenjiom</strong></p>
<ul>
<li><strong>Çocuklarda</strong></li>
<li><strong>Kalsifikasyon</strong></li>
<li><strong>Kistleri kolesterolden zengin, kahverengi-sarı sıvı (makine yağı)</strong></li>
</ul></li>
<li><p><strong>Papiller Kraniyofarenjiom</strong></p>
<ul>
<li><strong>Erişkinlerde</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B121.png" class="r-stretch"><p><strong>Robbins and Cotran Pathologic Basis of Disease</strong></p>
</section>
<section id="section" class="slide level2">
<h2></h2>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B122.png" class="r-stretch"></section>
<section id="hipofiz-adenomuna-yaklaşım" class="slide level2">
<h2>Hipofiz adenomuna yaklaşım</h2>
</section>
<section id="dr.-serdar-balcı" class="slide level2">
<h2>Dr.&nbsp;Serdar Balcı</h2>
</section>
<section id="klinik-bilgi" class="slide level2">
<h2>Klinik bilgi</h2>
<ul>
<li><strong>Çocuklarda: PRL, ACTH</strong></li>
<li><strong>Hormon düzeylerinde artış</strong>
<ul>
<li><strong>Hiperprolaktinemi → nonspesifik</strong></li>
</ul></li>
<li><strong>Kitle etkisi</strong>
<ul>
<li><strong>Başağrısı</strong></li>
<li><strong>Görme alanı</strong></li>
<li><strong>Hipopituitarism</strong></li>
</ul></li>
<li><strong>D. insipid ve kraniel sinir arazı</strong>
<ul>
<li><strong>Öncelikle diğer tümörler, metastazlar</strong></li>
<li><strong>İnflamatuar süreçler</strong></li>
</ul></li>
</ul>
</section>
<section id="ameliyat" class="slide level2">
<h2>Ameliyat</h2>
<p><strong>Eğer hemen patolojiye gelecekse SF içeren tüpte gönderilebilir. (Otoliz, formolsüz diye not konan rapor sayısı)</strong></p>
<p><strong>Gazlı bezi unutun</strong></p>
<p><strong>Formaldehit</strong></p>
<p><strong>EM inceleme?</strong></p>
</section>
<section id="hipofiz-adenomu---frozen" class="slide level2">
<h2>Hipofiz adenomu - Frozen</h2>
<ul>
<li><strong>Doku genelde küçük</strong>
<ul>
<li><strong>Donma artefaktı</strong></li>
</ul></li>
<li><strong>Yayma</strong>
<ul>
<li><strong>Daha az doku yeterli</strong></li>
<li><strong>Deneyim gerektiriyor</strong></li>
</ul></li>
<li><strong>Tek tanısal materyal frozenda </strong> <em>harcanmış </em> <strong>olabilir</strong></li>
<li><strong>Frozen beklenmedik bir bulgu ile karşılaşınca uygulanabilir (başka tümör şüphesi)</strong></li>
<li><strong>İntraoperatif retikülin?</strong></li>
<li><strong>Cerrahi sınır?</strong></li>
</ul>
</section>
<section id="mikroadenom-frozen" class="slide level2">
<h2>Mikroadenom – Frozen?</h2>
</section>
<section id="adenohipofiz-1" class="slide level2">
<h2>Adenohipofiz</h2>
<p><strong>Lobüler yapı</strong></p>
<p><strong>Coğrafi dağılım</strong></p>
<p><strong>Tükrük bezi benzeri bezler gibi taklitçiler</strong></p>
</section>
<section id="ara-lob" class="slide level2">
<h2>Ara lob???</h2>
</section>
<section id="nörohipofiz" class="slide level2">
<h2>Nörohipofiz</h2>
</section>
<section id="suprasellar-kitleler---ddx" class="slide level2">
<h2>Suprasellar kitleler - Ddx</h2>
<p><strong>Pituisitom</strong></p>
<p><strong>Lenfositik/granülamatöz hipofizit</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>Gangliositom/Gangliositoadenom</strong></p>
<p><strong>Germ hücreli tümörler</strong></p>
<p><strong>Granüler hücrrli tümör</strong></p>
<p><strong>Plazmasitom</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>Paragangliom</strong></p>
<p><strong>Metastaz</strong></p>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B123.png" class="r-stretch"></section>
<section id="section-1" class="slide level2">
<h2></h2>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B124.png" class="r-stretch"></section>
<section id="sellar-kitleler" class="slide level2">
<h2>Sellar kitleler</h2>
<p><strong>Kraniyofarengiom</strong></p>
<p><strong>Rathke kleft kisti</strong></p>
<p><strong>Teratom</strong></p>
<p><strong>Kordoma</strong></p>
<p><strong>Germinom</strong></p>
<p><strong>Pilositik astrositom</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>İnflamasyon</strong></p>
<p><strong>Langerhans hücreli histiyositoz</strong></p>
<p><strong>Granüler hücreli tümör</strong></p>
<p><strong>Glezer et al, Rare Sellar Lesions, Endocrinol Metab Clin N Am 37 (2008) 195–211</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B125.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B126.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B127.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B128.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B129.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B130.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B131.jpg"></p>
</section>
<section id="section-2" class="slide level2">
<h2></h2>
<p><strong>Postmortem prevalence of pituitary adenoma is 14.4% </strong></p>
<p><strong>radiologic studies identify a lesion consistent with pituitary adenoma in 22.2% of the population</strong></p>
<p><strong>providing an overall estimated prevalence of 16.9%.</strong></p>
</section>
<section id="adenom---hiperplazi" class="slide level2">
<h2>Adenom - Hiperplazi</h2>
<ul>
<li><strong>Diffüz, nodüler</strong></li>
<li><strong>Hiperplazi</strong>
<ul>
<li><strong>Stimulus kesilince büyüme durur</strong></li>
<li><strong>Gebelik: laktotrop hücre proliferasyonu</strong></li>
<li><strong>Primer hipopituitarizm: tirotrop</strong></li>
<li><strong>Hipotalamik gangliositom, GHrH eksprese eden tümörler: somatotrop</strong></li>
<li>__ CrH: bronşial, gastroenterohepatik, adrenal, prostat endokrin tümörler__</li>
</ul></li>
</ul>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B132.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B133.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B134.png"></p>
</section>
<section id="hipofiz-adenomu-1" class="slide level2">
<h2>Hipofiz adenomu</h2>
</section>
<section id="ffpe-he" class="slide level2">
<h2>FFPE – H&amp;E</h2>
<ul>
<li><strong>H&amp;E</strong></li>
<li><strong>10 boyasız</strong>
<ul>
<li><strong>Retikülin</strong></li>
<li><strong>PAS?</strong></li>
<li><strong>MIB-1</strong></li>
<li><strong>p53</strong></li>
<li><strong>Hormonlar</strong></li>
</ul></li>
</ul>
<p><strong>Nükleus</strong></p>
<p><strong>Nükleol</strong></p>
<p><strong>Kromatin</strong></p>
<p><strong>Atipi?</strong></p>
<p><strong>Mitoz</strong></p>
<p><strong>Sitoplazma</strong></p>
<p><strong>Yapı</strong></p>
<p><strong>Papiller</strong></p>
<p><strong>Amiloid</strong></p>
<p><strong>Kalsifikasyon</strong></p>
<p><strong>Tedavi etkisi</strong></p>
</section>
<section id="retikülin-adenohipofiz-hiperplazi-adenom" class="slide level2">
<h2>Retikülin: Adenohipofiz, Hiperplazi, Adenom</h2>
</section>
<section id="hormon-belirteçleri" class="slide level2">
<h2>Hormon belirteçleri</h2>
</section>
<section id="gh" class="slide level2">
<h2>GH</h2>
</section>
<section id="gh-ck8" class="slide level2">
<h2>GH – CK8</h2>
</section>
<section id="prolaktin" class="slide level2">
<h2>Prolaktin</h2>
</section>
<section id="prolaktin-ck8" class="slide level2">
<h2>Prolaktin – CK8</h2>
</section>
<section id="tsh" class="slide level2">
<h2>TSH</h2>
</section>
<section id="fsh" class="slide level2">
<h2>FSH</h2>
</section>
<section id="lh" class="slide level2">
<h2>LH</h2>
</section>
<section id="acth" class="slide level2">
<h2>ACTH</h2>
</section>
<section id="acth---mikroadenom" class="slide level2">
<h2>ACTH - mikroadenom</h2>
<p><strong>Retikülin ve ACTH IHK’sı gerekli</strong></p>
<p><strong>Yoğun granüllü</strong></p>
<p><strong>Bazofilik hücreler</strong></p>
<p><strong>PAS +</strong></p>
<p><strong>CAM 5.2, CK7, CK8</strong></p>
</section>
<section id="acth--crooke-değişiklik" class="slide level2">
<h2>ACTH- Crooke değişiklik</h2>
<ul>
<li><strong>Tümörsüz alanda (genellikle kortikotroplarda)</strong></li>
<li><strong>Dolaşımdaki artmış glukokortikoid varlığını yansıtır</strong>
<ul>
<li><strong>Pituiter kortikotrop adenom</strong></li>
<li><strong>Ektopik ACTH sekresyonu</strong></li>
<li><strong>Primer adrenal patolojiler</strong></li>
<li><strong>İatrojenik</strong></li>
</ul></li>
<li><strong>Adenom görülmediyse mikroadenom varlığı araştırılmalı (1-2 mm’lik seri kesitler, retikülin ve ACTH ile bakılarak)</strong></li>
<li><strong>Adenom görülmezse klinikopatolojik korelasyon gerektirir</strong></li>
</ul>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B135.png" class="r-stretch"></section>
<section id="acth--crooke-cell" class="slide level2">
<h2>ACTH- Crooke cell</h2>
<ul>
<li><strong>Adenom görülmediyse mikroadenom varlığı araştırılmalı</strong>
<ul>
<li><strong>1-2 mm’lik seri kesitler</strong></li>
<li><strong>Retikülin ve ACTH ile bakılarak</strong></li>
</ul></li>
<li><strong>Adenom görülmezse klinikopatolojik korelasyon gerektirir</strong>
<ul>
<li><strong>Hâlâ sellada adenom var mı?</strong></li>
<li><strong>Kortikoid yüksekliğinin başka nedenleri</strong></li>
<li><strong>Aspiratörde ya da seri kesitlerde kaybolan adenom?</strong></li>
</ul></li>
</ul>
</section>
<section id="acth-crooke-değişiklik-yok-adenom-yok" class="slide level2">
<h2>ACTH Crooke değişiklik yok, adenom yok</h2>
<ul>
<li><strong>Kortikotrop hiperplazi?</strong>
<ul>
<li><strong>Patolojik değerlendirme zor olabilir</strong></li>
</ul></li>
<li><strong>Psödo Cushing</strong></li>
</ul>
</section>
<section id="acth-crooke-cell-adenoma" class="slide level2">
<h2>ACTH – Crooke cell adenoma</h2>
<p><strong>Adenomatöz hücrelerin sitoplazmasında yoğun birikim</strong></p>
<p><strong>Nükleer pleomorfizm, iri hücre</strong></p>
<p><strong>DDX: gangliositom, metastaz</strong></p>
<p><strong>ACTH +</strong></p>
<p><strong>Yoğun halka şeklinde keratin birikimi</strong></p>
<p><strong>CAM 5.2 +</strong></p>
</section>
<section id="p53" class="slide level2">
<h2>p53</h2>
</section>
<section id="ki-67" class="slide level2">
<h2>Ki-67</h2>
</section>
<section id="pit-1" class="slide level2">
<h2>Pit-1</h2>
</section>
<section id="er-α" class="slide level2">
<h2>ER-α</h2>
</section>
<section id="mukozada-ekilim" class="slide level2">
<h2>Mukozada ekilim?</h2>
</section>
<section id="serum-ihk-korelasyonu" class="slide level2">
<h2>Serum – IHK korelasyonu</h2>
</section>
<section id="otopside-inceleme" class="slide level2">
<h2>Otopside inceleme</h2>
<p><strong>Stalk yüksekten kesilmeli</strong></p>
<p><strong>Sella kontrol edilmeli</strong></p>
<p><strong>Dorsum sella dan açılarak intakt çıkartılmaya çalışılmalı</strong></p>

<img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B136.png" class="r-stretch"></section>
<section id="alıntı-slaytlar" class="slide level2">
<h2>Alıntı slaytlar</h2>
</section>
<section id="section-3" class="slide level2">
<h2></h2>
</section>
<section id="adenohipofiz-2" class="slide level2">
<h2>Adenohipofiz</h2>
<p><strong>Lateral kanat</strong></p>
<p><strong>Mukoid wedge</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B137.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B138.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B139.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B140.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B141.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B142.png"></p>
</section>
<section id="hipofiz-adenomu-sınıflandırması" class="slide level2">
<h2>Hipofiz adenomu sınıflandırması</h2>
<p><strong>Cerrahi, radyoloji</strong></p>
<ul>
<li><strong>İnvazif</strong>
<ul>
<li><strong>Dura</strong></li>
<li><strong>Kemik</strong></li>
<li><strong>Sinüsler</strong></li>
</ul></li>
<li><strong>Non-invazif</strong></li>
</ul>
<p><strong>Hormon aktif</strong></p>
<p><strong>Nonfonksiyone</strong></p>
<p><strong>Mikroadenom &lt;1cm</strong></p>
<p><strong>Makroadenom &gt;1cm</strong></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B143.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B144.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B145.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B146.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B147.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B148.jpg"></p>
</section>
<section id="büyüme-hormonu-adenomu" class="slide level2">
<h2>Büyüme Hormonu Adenomu</h2>
<p><strong>%10</strong></p>
<p><strong>%25-30</strong></p>
<p><strong>Gigantizm, akromegali</strong></p>
<p><strong>İnvaziv makroadenom</strong></p>
<p><strong>IGF-1</strong></p>
</section>
<section id="yoğun-granüllü-gh-adenomu" class="slide level2">
<h2>Yoğun granüllü GH adenomu</h2>
<p><strong>Yuvarlak, polihedral, asidofilik</strong></p>
<p><strong>Yaygın, kuvvetli sitoplazmik GH</strong></p>
<p><strong>Perinükleer CK8</strong></p>
<p><strong>Yarısında α-subünit pozitif</strong></p>
<p><strong>Pit-1 kuvvetli nükleer pozitif</strong></p>
<p><strong>EM sekretuvar granüller bol</strong></p>
</section>
<section id="seyrek-granüllü-gh-adenomu" class="slide level2">
<h2>Seyrek granüllü GH adenomu</h2>
<ul>
<li><p><strong>Küçük, yuvarlak, kısmen düzensiz hücreler</strong></p></li>
<li><p><strong>Fibröz cisimler</strong></p>
<ul>
<li><strong>Paranükleer soluk asidofilik küresel inklüzyon</strong></li>
<li><strong>LMWCK, CK8 pozitif</strong></li>
</ul></li>
<li><p><strong>Pleomorfizm, çok çekirdekli bizar hücreler</strong></p></li>
<li><p><strong>GH zayıf sitoplazmik</strong></p></li>
<li><p><strong>Pit-1 kuvvetli nükleer pozitif</strong></p></li>
<li><p><strong>Daha agresif</strong></p></li>
<li><p><strong>Multinükleer, pleomorfizm</strong></p>
<ul>
<li><strong>Prognostik değil</strong></li>
</ul></li>
<li><p><strong>Makroadenom, invazif</strong></p></li>
<li><p><strong>Otokrin</strong></p>
<ul>
<li><strong>GHrH salgılıyor</strong></li>
</ul></li>
</ul>
</section>
<section id="prl-hücre-adenomu" class="slide level2">
<h2>PRL hücre adenomu</h2>
<ul>
<li><strong>%25-30</strong></li>
<li><strong>Serum PRL düzeyi genelde tümör boyutu ile paralel</strong>
<ul>
<li><strong>&gt;150ng/mL tanısal</strong></li>
<li><strong>Daha düşük değerler bası etkisini yansıtır</strong></li>
</ul></li>
<li><strong>Kadınlarda mikroadenom şeklinde</strong>
<ul>
<li><strong>Galaktore, amenore</strong></li>
</ul></li>
<li><strong>Erkeklerde</strong>
<ul>
<li><strong>Libido azalması, impotans</strong></li>
</ul></li>
<li><strong>Mikroadenom lateral ve posteriorda</strong></li>
<li><strong>Genelde diffüz, nadiren papiller</strong></li>
<li><strong>Nadir iri, uzun hücreler, belirgin membran</strong></li>
</ul>
<p><strong>Amiloid depolanması, kalsifikasyon</strong></p>
<p><strong>Pitüiter taş</strong></p>
</section>
<section id="seyrek-granüllü-laktotrop-adenomu" class="slide level2">
<h2>Seyrek granüllü laktotrop adenomu</h2>
<ul>
<li><strong>Kromofob, amfofilik</strong>
<ul>
<li><strong>Belirgin </strong> <em>rough</em> __ endoplazmik retikulum içerir__</li>
</ul></li>
<li><strong>Paranükleer (golgi) paterninde PRL pozitif</strong></li>
<li><strong>Pit-1 nükleer kuvvetli</strong></li>
</ul>
</section>
<section id="yoğun-granüllü-laktotrop-adenomu" class="slide level2">
<h2>Yoğun granüllü laktotrop adenomu</h2>
<p><strong>Nadir</strong></p>
</section>
<section id="dopamin-agonisti-tedavisi-etkisi" class="slide level2">
<h2>Dopamin agonisti tedavisi etkisi</h2>
<p><strong>Atrofi</strong></p>
<p><strong>Hücre boyutunda küçülme</strong></p>
<p><strong>Sitoplazmada büzüşme</strong></p>
<p><strong>N/C oranında artma</strong></p>
<p><strong>İnterstisyel ve perivasküler fibrozis</strong></p>
</section>
<section id="tsh-hücre-adenomu" class="slide level2">
<h2>TSH hücre adenomu</h2>
<p><strong>Nadir</strong></p>
<p><strong>İnvaziv</strong></p>
<p><strong>Solid, sinüzoidal patern</strong></p>
<p><strong>Stromal fibrozis, psammom cisimleri</strong></p>
<p><strong>Hücre sınırları belirsiz kromofob adenom</strong></p>
<p><strong>Nükleer pleomorfizm olabilir</strong></p>
<p><strong>PAS sitoplazmik granüller</strong></p>
<p><strong>Sitoplazma: α-subünit, β-TSH</strong></p>
<p><strong>Nükleer Pit-1</strong></p>
<p><strong>Plurihormonal ekspresyon izlenebilir</strong></p>
</section>
<section id="acth-hücre-adenomu" class="slide level2">
<h2>ACTH hücre adenomu</h2>
<ul>
<li><strong>%10-15</strong></li>
<li><strong>Makroskopik: kırmızı ve yumuşak mikroadenom</strong></li>
<li><strong>Seri kesitlere rağmen izlenemeyebilir</strong></li>
<li><strong>Nadir kavernöz sinüs invazyonu</strong>
<ul>
<li><strong>Klinik ve biyokimyasal semptom yok</strong></li>
<li><strong>Sessiz</strong></li>
</ul></li>
</ul>
<p><strong>Diffüz, sinüzoidal</strong></p>
<p><strong>Bazofilik, amfofilik, monomorfik, yuvarlak</strong></p>
<p><strong>Kuvvetli PAS pozitif</strong></p>
<p><strong>Crooke hyalen değişim</strong></p>
<p><strong>Pleomorfizm</strong></p>
<p><strong>Mitoz nadir</strong></p>
<p><strong>ACTH, β-LPH ve/veya β-endorfin</strong></p>
<p><strong>Cushing hastalığı (pitüiter ACTH fazlalığı)</strong></p>
<p><strong>Nelson zemininde gelişen</strong></p>
<p><strong>Crooke cell adenoma</strong></p>
<p><strong>Sessiz kortikotrop adenomlar</strong></p>
</section>
<section id="cushing-hastalığı-pitüiter-acth-fazlalığı" class="slide level2">
<h2>Cushing hastalığı (pitüiter ACTH fazlalığı)</h2>
</section>
<section id="gonadotrop-hücre-adenomu" class="slide level2">
<h2>Gonadotrop hücre adenomu</h2>
<p><strong>Nadir?</strong></p>
<p><strong>Fonksiyonel olanlar erkeklerde daha sık</strong></p>
<p><strong>Sessiz adenomlarda IHK ile tanı konur</strong></p>
<p><strong>Makroadenom</strong></p>
<p><strong>Supra, parasellar</strong></p>
<p><strong>Sinüzoid, psödorozet</strong></p>
<p><strong>Kanama, nekroz olabilir</strong></p>
<p><strong>PAS negatif, onkositik olabilir</strong></p>
<p><strong>α-subünit, β-FSH (daha sık), β-LH pozitif</strong></p>
</section>
<section id="plurihormonal-adenomlar" class="slide level2">
<h2>Plurihormonal Adenomlar</h2>
<ul>
<li><strong>Pit-1</strong>
<ul>
<li><strong>Karışık somatotrop-laktotrop</strong>
<ul>
<li><strong>Akromegali, stalka bası</strong></li>
<li><strong>İki farklı hücre tipi</strong></li>
</ul></li>
<li><strong>Mammosomatotrop</strong>
<ul>
<li><strong>Klinik sakin, akromegali, hiperPRL</strong></li>
<li><strong>Aynı hücrede GH ve PRL</strong></li>
</ul></li>
<li><strong>Asidofil kök hücre</strong>
<ul>
<li><strong>Klinik sakin veya hiperPRL</strong></li>
<li><strong>Kromofob</strong></li>
<li><strong>İnvaziv</strong></li>
<li><strong>Paranükleer vakuol</strong></li>
<li><strong>Agresif seyir</strong></li>
</ul></li>
<li><strong>Plurihormonal GH üreten adenomlar</strong>
<ul>
<li><strong>Yoğun granüllü GH adenomu</strong></li>
<li><strong>PRL, α-subünit, β-TSH, β-FSH, β-LH</strong></li>
</ul></li>
</ul></li>
<li><strong>ACTH-α subünit</strong></li>
<li><strong>LH/FSH-PRL-β-endorfin</strong></li>
<li><strong>GH-ACTH</strong></li>
<li><strong>PRL-TSH</strong></li>
</ul>
</section>
<section id="null-hücre-adenomu" class="slide level2">
<h2>Null Hücre Adenomu</h2>
<p><strong>%20, giderek düşüyor</strong></p>
<p><strong>Suprasellar, parasellar invazyon</strong></p>
<p><strong>Kavitasyon, kanama</strong></p>
<p><strong>Yuvarlak, poligonal, kromofob</strong></p>
<p><strong>Diffüz, papiller</strong></p>
<p><strong>Pleomorfizm, mitoz nadir</strong></p>
</section>
<section id="invaziv" class="slide level2">
<h2>İnvaziv</h2>
<p><strong>Kemik</strong></p>
<p><strong>Kavernöz sinüs</strong></p>
<p><strong>Nazofarenks</strong></p>
<p><strong>Dura</strong></p>
<ul>
<li><strong>Agresif davranış</strong>
<ul>
<li><strong>Rekürrens</strong></li>
<li><strong>Hormon düzeyi normale dönmez</strong></li>
</ul></li>
<li><strong>Dura invazyonu sık</strong>
<ul>
<li><strong>Agresif değil</strong></li>
</ul></li>
</ul>
</section>
<section id="atipik-adenom" class="slide level2">
<h2>Atipik adenom</h2>
<ul>
<li><strong>Biyolojik</strong>
<ul>
<li><strong>Agresif davranış</strong></li>
<li><strong>Rekürrens</strong></li>
</ul></li>
<li><strong>Ki-67&gt;%3</strong></li>
<li><strong>p53 pozitif</strong></li>
<li><strong>Metastaz yaparlar mı?</strong></li>
</ul>
</section>
<section id="hipofiz-karsinomu" class="slide level2">
<h2>Hipofiz karsinomu</h2>
<ul>
<li><strong>BOS ya da sistemik yayılımla tanı konur</strong></li>
<li><strong>Erişkinlerde</strong></li>
<li><strong>Nadir</strong></li>
<li><strong>PRL, GH</strong></li>
<li><strong>ACTH olanlar Nelson zemininde</strong></li>
<li><strong>İnvazyon, pleomorfizm, mitoz ve nekroz izlenir</strong>
<ul>
<li><strong>Ancak tanısal ya da prediktif değildir</strong></li>
</ul></li>
</ul>
</section>
<section id="cadillac-approach" class="slide level2">
<h2>Cadillac approach</h2>
<p><strong>Acta Neuropathol (2006) 111: 68–70</strong></p>
</section>
<section id="section-4" class="slide level2">
<h2></h2>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B149.png"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B150.png"></p>
</section>
<section id="hipofiz-adenomu-2" class="slide level2">
<h2>Hipofiz adenomu</h2>
</section>
<section id="dialar" class="slide level2">
<h2>dialar</h2>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B151.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B152.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B153.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B154.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B155.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B156.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B157.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B158.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B159.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B160.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B161.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B162.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B163.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B164.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B165.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B166.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B167.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B168.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B169.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B170.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B171.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B172.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B173.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B174.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B175.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B176.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B177.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B178.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B179.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B180.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B181.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B182.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B183.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B184.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B185.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B186.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B187.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B188.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B189.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B190.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B191.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B192.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B193.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B194.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B195.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B196.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B197.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B198.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B199.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1100.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1101.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1102.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1103.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1104.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1105.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1106.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1107.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1108.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1109.jpg"></p>
<p><img data-src="./img-local/Hipofiz-Hastal%C4%B1klar%C4%B1110.jpg"></p>
<div class="footer footer-default">

</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="hipofiz-hastaliklari_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>